1017782-79-4

Basic information

• Product Name: 5-(4-BOC-piperazino)-2-nitroanisole
• Synonyms: 5-(4-BOC-piperazino)-2-nitroanisole;1-benzyl-4-(3-methoxy-4-nitrophenyl)piperazine;t-Butyl 4-(3-methoxy-4-nitrophenyl)piperazine-1-carboxylate
• CAS NO: 1017782-79-4
• Molecular Formula: C₁₆H₂₃N₃O₅
• Molecular Weight: 337
• Mol File: 1017782-79-4.mol
• Article Data: 25

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5-(4-BOC-piperazino)-2-nitroanisole(CAS DataBase Reference)
• NIST Chemistry Reference: 5-(4-BOC-piperazino)-2-nitroanisole(1017782-79-4)
• EPA Substance Registry System: 5-(4-BOC-piperazino)-2-nitroanisole(1017782-79-4)

Safety Data

• Hazardous Substances Data: 1017782-79-4(Hazardous Substances Data)

Usage

General Description

5-(4-BOC-piperazino)-2-nitroanisole is a chemical compound with the molecular formula C15H22N4O4. It is a nitro-containing compound with a molecular weight of 314.36 g/mol. The compound has a piperazine ring with a tert-butyloxycarbonyl (BOC) protecting group on the nitrogen atom. The 2-nitroanisole moiety consists of a methoxy group attached to a nitro group. 5-(4-BOC-piperazino)-2-nitroanisole has potential applications in pharmaceuticals and organic synthesis, and its properties make it interesting for further research and development.

Upstream product

• 110-85-0 piperazine 
• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 446-36-6 5-fluoro-2-nitrophenol 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 6627-53-8 1-chloro-3-methoxy-4-nitrobenzene 

Downstream Products

• 1246532-96-6 tert-butyl 4-(4-amino-3-methoxy-phenyl)-piperazine-1-carboxylate 
• 1390655-14-7 8-(2,6-dichlorobenzyl)-6-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}-1,2,3,4-tetrahydro-5H-pyrido[2,3-e][1,4]diazepin-5-one 
• 1390656-56-0 tert-butyl 4-(4-(8-chloro-5-oxo-2,3,4,5-tetrahydro-1H-pyrido[2,3-e][1,4]diazepin-6-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390655-13-6 7-(2,6-dichlorobenzyl)-5-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}pyrido[3,4-d]pyridazin-4-ol mono-trifluoroacetate 
• 1390656-52-6 tert-butyl 4-(4-(7-(2,6-dichlorobenzyl)-4-hydroxypyrido[3,4-d]pyridazin-5-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390656-51-5 tert-butyl 4-(4-(7-bromo-4-hydroxypyrido[3,4-d]pyridazin-5-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390656-09-3 2-(2-chlorophenoxy)-4-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}pyrido[2,3-d]pyridazin-5(6H)-one 
• 1390657-72-3 tert-butyl 4-(4-((2-(2-chlorophenoxy)-5-oxo-5,6-dihydropyrido[2,3-d]pyridazin-4-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390656-07-1 7-(cyclopentyloxy)-5-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}pyrido[3,4-d]pyridazin-4-ol 
• 1390656-03-7 7-[(3-fluoropyridin-4-yl)oxy]-5-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}pyrido[3,4-d]pyridazin-4-ol 
• 1390657-64-3 tert-butyl 4-(4-((7-((3-fluoropyridin-4-yl)oxy)-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-yl)amino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390655-99-8 7-(2,3-dichlorophenoxy)-5-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}pyrido[3,4-d]pyridazin-4(3H)-one 
• 1390657-60-9 tert-butyl 4-(4-(7-(2,3-dichlorophenoxy)-4-oxo-3,4-dihydropyrido[3,4-d]pyridazin-5-ylamino)-3-methoxyphenyl)piperazine-1-carboxylate 
• 1390655-97-6 5-{[2-methoxy-4-(piperazin-1-yl)phenyl]amino}-7-[(2,3,4-trichlorophenyl)amino]pyrido[3,4-d]pyridazin-4(3H)-one 

Relevant articles and documents

Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL

MyD88 gene mutation has been identified as one of the most prevalent driver mutations in the activated B-cell-like diffuse large B-cell lymphoma (ABC DLBCL). The published literature suggests that interleukin-1 receptor-associated kinase 1 (IRAK1) is an essential gene for ABC DLBCL harboring MyD88 mutation. Importantly, the scaffolding function of IRAK1, rather than its kinase activity, is required for tumor cell survival. Herein, we present our design, synthesis, and biological evaluation of a novel series of potent and selective IRAK1 degraders. One of the most potent compounds, Degrader-3 (JNJ-1013), effectively degraded cellular IRAK1 protein with a DC50 of 3 nM in HBL-1 cells. Furthermore, JNJ-1013 potently inhibited IRAK1 downstream signaling pathways and demonstrated strong anti-proliferative effects in ABC DLBCL cells with MyD88 mutation. This work suggests that IRAK1 degraders have the potential for treating cancers that are dependent on the IRAK1 scaffolding function.

Conformational, vibrational and DFT studies of a newly synthesized arylpiperazine-based drug and evaluation of its reactivity towards the human GABA receptor

This study reports a computational assessment of important biochemical properties and vibrational assignments for the synthesized 1-(4-(3-methoxy-4-nitrophenyl)piperazin-1-yl)ethanone (MNPE). MNPE is related to the commonly used arylpiperazine-based drugs

TYROSINE KINASE NON-RECEPTOR 1 (TNK1) INHIBITORS AND USES THEREOF

Provided herein is a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein values for the variables (e.g, X11, X22, R11, R22, R33, R44, R55, R66, R77, R88, m, n) are as described herein. Compounds of Formula I, pharmaceutically acceptable salts thereof, pharmaceutical compositions of either of the foregoing, and combinations of any of the foregoing can be used to treat tyrosine kinase non- receptor 1 (TNK1)-mediated diseases, disorders and conditions.

PROTEIN DEGRADATION TARGETING COMPOUND, ANTI-TUMOR APPLICATION, INTERMEDIATE THEREOF AND USE OF INTERMEDIATE

The present disclosure relates to compounds of formula (I) and their anti-tumor uses, and their intermediates of formula (III), intermediates of formula (IV), and uses of the intermediates. The compound of formula (I) has a degrading effect on a specific target protein, which is mainly composed of three parts. The first part is a small molecule compound (SMBP, Small Molecules Binding Protein) that can bind to a protein, the second part LIN is a linker, and the three-part ULM is a ubiquitin ligand (ULM, Ubiquitin Ligase Binding Moiety), wherein SMBP is covalently bound to LIN, and LIN is covalently bound to ULM. A series of compounds designed and synthesized in the present disclosure have a wide range of pharmacological activities, including the functions of degrading specific proteins and/or inhibiting activities of specific proteins, and thus can be used in related tumor treatments.